Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,823 | 310 | 2,478 |
| Samples | 1,097 | 159 | 923 |
| Peptides | 655 | 97 | 579 |
Function
ERBB3 · Erb-b2 receptor tyrosine kinase 3
This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 615 amino-acid changes on canonical ENST00000267101 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ERBB3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ERBB3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Bladder Carcinoma | 4/58 7% | 87/956 9% |
| Endometrial Carcinoma | 7/42 17% | 47/612 8% |
| Unknown | 1/10 10% | 2/29 7% |
| Gastric Carcinoma | 7/74 9% | 133/1809 7% |
| Colorectal Carcinoma | 22/143 15% | 146/3239 5% |
| Biliary Tract Carcinoma | 1/54 2% | 44/950 5% |
| Cervical Carcinoma | 2/35 6% | 18/422 4% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| Hodgkins Lymphoma | 3/16 19% | 2/122 2% |
| Melanoma | 9/210 4% | 59/1899 3% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Other Solid Cancers | 4/94 4% | 43/1515 3% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 2/71 3% |
| Non-Small Cell Lung Carcinoma | 19/304 6% | 26/1390 2% |
| Non-Cancerous | 4/104 4% | 18/830 2% |
| Chondrosarcoma | 0/14 0% | 2/75 3% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Esophageal Carcinoma | 0/23 0% | 17/769 2% |
| Ovarian Carcinoma | 8/109 7% | 15/998 2% |
| Breast Carcinoma | 8/144 6% | 62/3264 2% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 15/810 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Head and Neck Carcinoma | 1/85 1% | 29/1574 2% |
| Plasma Cell Myeloma | 3/44 7% | 3/305 1% |
| Neuroendocrine Tumour | 3/154 2% | 9/577 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 11/752 1% |
| Burkitts Lymphoma | 3/32 9% | 0/196 0% |
| Pancreatic Carcinoma | 4/89 4% | 15/1611 1% |
Mutation Distribution
Where ERBB3 is mutated · all tissues, split by cell line vs tissue
How many mutations in ERBB3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,823 mutations in ERBB3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|